Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Common Equity (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Common Equity for 16 consecutive years, with $368.0 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 47.51% to $368.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $368.0 million through Dec 2025, down 47.51% year-over-year, with the annual reading at $368.0 million for FY2025, 47.51% down from the prior year.
  • Common Equity for Q4 2025 was $368.0 million at Myriad Genetics, down from $372.8 million in the prior quarter.
  • The five-year high for Common Equity was $968.5 million in Q3 2021, with the low at $368.0 million in Q4 2025.
  • Average Common Equity over 5 years is $760.9 million, with a median of $771.6 million recorded in 2023.
  • The sharpest move saw Common Equity rose 9.85% in 2021, then plummeted 49.05% in 2025.
  • Over 5 years, Common Equity stood at $967.8 million in 2021, then dropped by 8.47% to $885.8 million in 2022, then fell by 11.58% to $783.2 million in 2023, then fell by 10.48% to $701.1 million in 2024, then tumbled by 47.51% to $368.0 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $368.0 million, $372.8 million, and $388.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.